Christopher L Tinkle1, Noelle L Williams2, Huiyun Wu3, Jianrong Wu4, Sue C Kaste5, Barry L Shulkin6, Aimee C Talleur7, Jamie E Flerlage8, Melissa M Hudson8, Monika L Metzger8, Matthew J Krasin9. 1. Department of Radiation Oncology, St. Jude Children's Hospital, Memphis, United States. Electronic address: christopher.tinkle@stjude.org. 2. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, United States. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, United States. 4. Department of Biostatistics, University of Kentucky, Lexington, United States. 5. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, United States; Department of Radiology, University of Tennessee Health Science Center, Memphis, United States; Department of Oncology, St. Jude Children's Research Hospital, Memphis, United States. 6. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, United States; Department of Radiology, University of Tennessee Health Science Center, Memphis, United States. 7. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, United States. 8. Department of Oncology, St. Jude Children's Research Hospital, Memphis, United States. 9. Department of Radiation Oncology, St. Jude Children's Hospital, Memphis, United States.
Abstract
BACKGROUND AND PURPOSE: The use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT. MATERIALS AND METHODS: Forty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT. RESULTS: RT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5 Gy and 30.6 Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT = 3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2-30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2-92.6%) and 88.5% (95% CI, 79.5-98.6%), respectively. Inadequate response to salvage systemic therapy (p = 0.048) and male sex (p = 0.049) were significantly associated with LF after salvage RT. CONCLUSION: rrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF. Published by Elsevier B.V.
BACKGROUND AND PURPOSE: The use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT. MATERIALS AND METHODS: Forty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT. RESULTS: RT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5 Gy and 30.6 Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT = 3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2-30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2-92.6%) and 88.5% (95% CI, 79.5-98.6%), respectively. Inadequate response to salvage systemic therapy (p = 0.048) and male sex (p = 0.049) were significantly associated with LF after salvage RT. CONCLUSION: rrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF. Published by Elsevier B.V.
Entities:
Keywords:
Hodgkin lymphoma; Local failure; Pediatric; Radiation therapy; Recurrent; Relapsed
Authors: Robert Chen; Joycelynne M Palmer; Sandra H Thomas; Ni-Chun Tsai; Len Farol; Auayporn Nademanee; Stephen J Forman; Ajay K Gopal Journal: Blood Date: 2012-05-18 Impact factor: 22.113
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: Monika L Metzger; Melissa M Hudson; Matthew J Krasin; Jianrong Wu; Sue C Kaste; Larry E Kun; John T Sandlund; Scott C Howard Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski Journal: Lancet Date: 2015-03-19 Impact factor: 79.321
Authors: Sara Stoneham; Sue Ashley; C Ross Pinkerton; W Hamish Wallace; Ananth Gouri Shankar Journal: J Pediatr Hematol Oncol Date: 2004-11 Impact factor: 1.289